- Home
- CPOP vs EQ Comparison
CPOP vs EQ Comparison
Compare CPOP & EQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CPOP
- EQ
- Stock Information
- Founded
- CPOP 2007
- EQ 2017
- Country
- CPOP China
- EQ United States
- Employees
- CPOP N/A
- EQ N/A
- Industry
- CPOP Services-Misc. Amusement & Recreation
- EQ Biotechnology: Pharmaceutical Preparations
- Sector
- CPOP Consumer Discretionary
- EQ Health Care
- Exchange
- CPOP Nasdaq
- EQ Nasdaq
- Market Cap
- CPOP 61.0M
- EQ 57.8M
- IPO Year
- CPOP 2021
- EQ 2018
- Fundamental
- Price
- CPOP $0.57
- EQ $1.06
- Analyst Decision
- CPOP
- EQ Hold
- Analyst Count
- CPOP 0
- EQ 1
- Target Price
- CPOP N/A
- EQ $1.00
- AVG Volume (30 Days)
- CPOP 90.8K
- EQ 407.3K
- Earning Date
- CPOP 06-30-2025
- EQ 11-13-2025
- Dividend Yield
- CPOP N/A
- EQ N/A
- EPS Growth
- CPOP N/A
- EQ N/A
- EPS
- CPOP N/A
- EQ N/A
- Revenue
- CPOP $65,186,721.00
- EQ $4,392,000.00
- Revenue This Year
- CPOP N/A
- EQ N/A
- Revenue Next Year
- CPOP N/A
- EQ N/A
- P/E Ratio
- CPOP N/A
- EQ N/A
- Revenue Growth
- CPOP 108.29
- EQ N/A
- 52 Week Low
- CPOP $0.46
- EQ $0.27
- 52 Week High
- CPOP $2.61
- EQ $2.35
- Technical
- Relative Strength Index (RSI)
- CPOP 33.27
- EQ 41.42
- Support Level
- CPOP $0.56
- EQ $1.31
- Resistance Level
- CPOP $0.65
- EQ $1.58
- Average True Range (ATR)
- CPOP 0.06
- EQ 0.14
- MACD
- CPOP 0.00
- EQ -0.04
- Stochastic Oscillator
- CPOP 5.22
- EQ 36.27
About CPOP Pop Culture Group Co. Ltd
Pop Culture Group Co Ltd hosts entertainment events, operates hip-hop-related online programs, and provides event planning and execution services and marketing services to corporate clients. It generates revenue from Event Hosting business by providing sponsorship packages to advertisers in exchange for sponsorship fees and by selling tickets for those concerts. The company has various operations services out of which Brand Promotion earns maximum revenue, following by Event Hosting, and Event Planning and Execution.
About EQ Equillium Inc.
Equillium Inc is a clinical-stage biotechnology company engaged in developing novel therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. The company intends to commercialize its product candidates either independently or through partnerships, or otherwise monetize its pipeline through strategic transactions. Itolizumab (EQ001), a clinical-stage product candidate, is an anti-CD6 immune-modifying monoclonal antibody, or mAb, that selectively targets the CD6-ALCAM signaling pathway to downregulate pathogenic T effector cells while preserving T regulatory cells critical for maintaining a balanced immune response. The company's other clinical-stage and pre-clinical-stage candidates include EQ101 and EQ302.